Cryoport, Inc.CYRX

Cryoport Inc. last week filed its 10-Q for the quarter ended March 31, 2026, showing revenue of $47.8 million, a net loss of $10.5 million, and diluted EPS of -$0.25 on 49.9 million shares. Operating cash flow clocked in at a modest $3.7 million, while capex gobbled $10 million, leaving the balance sheet with $272.9 million in cash and $130.7 million in short-term investments against $268.6 million in liabilities. The company markets itself as the global leader in temperature-controlled supply chains for life sciences, but the filing quietly concedes that one customer alone delivered 10.8% of revenue and foreign sales rose to $12.8 million (26.9% of the total), a concentration risk that belies the ‘diversified platform’ narrative.

Cryoport’s product story centres on cryogenic storage systems, clinical-trial support, and biostorage for regenerative medicine, with a growing focus on cell and gene therapy. The homepage and business-unit pages trumpet the firm as ‘the world’s largest manufacturer of cryogenic storage systems’ and a ‘trusted provider’ of supply-chain solutions for irreplaceable materials. Yet the latest earnings show a company still burning cash while preaching scale, with R&D at $3.9 million and inventory-despite the hype-actually falling by $1.3 million.

The SEC filing also confirms that Cryoport’s revenue from foreign customers grew to $12.8 million in Q1 2026 from $8.8 million a year earlier, but that still represents less than 27% of total revenue; no other single customer crossed the 10% threshold. Research and development expense climbed to $3.9 million, while cash used in operations was $3.7 million and capex was $10 million, illustrating the classic biotech paradox: spend now to monetise later, but the cash runway keeps shortening. The firm’s own press release pipeline shows a contract win with Verismo Therapeutics for IntegriCell cryopreservation services, yet the 10-Q contains no updated guidance or segment-level breakouts that would quantify the deal’s contribution. Investors are left parsing the same headline numbers while the company talks about ‘enabling the future of medicine’ without attaching a price tag to the privilege.

For those who like their filings with a side of optics, Cryoport’s June filing trail reads like a liquidity housekeeping exercise. On June 22 it filed an S-8 shelf for unspecified securities; it simultaneously filed Form 4s for insiders and two Rule 144 notices indicating affiliates were selling shares. The juxtaposition is instructive: the marketing site glows with images of vials and therapies, while the regulatory filing trail quietly manages the mechanics of dilution and secondary liquidity. The company’s investor site also confirms that a second-quarter 2026 earnings release is scheduled for August 6, 2026, giving analysts six weeks to decide whether the next set of numbers will show genuine leverage or merely more leverage.

The company’s balance sheet remains robust on paper-$763.6 million in assets versus $268.6 million in liabilities-but the income statement tells a less flattering tale. With a $10.5 million net loss on $47.8 million of revenue, Cryoport is still in the capital-intensive phase of its lifecycle, funding growth with a mix of cash burn and shareholder dilution. The filing does not break out free cash flow, nor does it quantify the impact of the Verismo deal beyond a press release. Until the August update, the source requires readers to triangulate between the global-leader narrative, the single-customer concentration, and the quarterly cash burn to decide whether the premium multiple is justified by fundamentals or by promise.

For market context, the stock trades on NASDAQ under the ticker CYRX, but the regional exchange and filing jurisdiction remain U.S.-centric; there is no suggestion in the supplied sources of a dual-listing or foreign primary venue. The company’s own imagery leans heavily on biotech aesthetics-vials, lab coats, futuristic pipelines-yet the hard data in the 10-Q shows a firm that is still, at heart, a cash-consuming supplier in a race against time to convert R&D into recurring revenue before the clock runs out. The next catalyst is the August 6, 2026 earnings release, followed by any updated commentary on the Verismo contract’s scale and contribution.